Iridium Acquisition Under Fire as Shareholder Investigation Questions Sale Price

What happened

Kahn Swick & Foti is investigating the proposed $27 cash plus Rocket Lab stock offer for Iridium, questioning the adequacy of the price and process. The offer price appears well below the $51.40 per share level at which Iridium traded before the announcement and the $50 base case valuation in the latest DeepValue analysis. The investigation introduces uncertainty into a deal that would preempt the company's strategic initiatives, including the Aireon acquisition and NTN Direct launch. Iridium reported steady Q1 2026 results with $158M services revenue and $21.6M net income, but its high leverage and pending EMSS government contract renewal had kept the stock rated 'WAIT' by DeepValue. The shareholder probe could pressure Rocket Lab to raise its bid or derail the transaction, forcing Iridium back to standalone execution on its catalysts.

Implication

If the deal collapses or is renegotiated, the DeepValue thesis of waiting for Aireon close and EMSS renewal clarity becomes relevant again; the investigation may result in a higher bid that better reflects Iridium's intrinsic value. However, the process introduces legal and timing risks; long-term investors should monitor developments but avoid building a full position until the M&A uncertainty resolves.

Thesis delta

The proposed sale shifts the thesis from a wait-for-catalysts stance to an event-driven situation where the offer price is likely inadequate. The investigation could lead to a better deal for shareholders, but it also introduces risk of deal failure and a return to standalone uncertainties. The DeepValue thesis of waiting for Aireon close and EMSS clarity becomes secondary to the M&A process.